Trillium Therapeutics Receives FDA Clearance to Proceed With TTI-621 in Clinical Trial Targeting Solid Tumors and Mycosis Fungoides

Aug 17, 2016 TORONTO - Trillium Therapeutics Inc. (TRIL)(TR.TO), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the US Food and Drug Administration (FDA) has provided the company clearance to initiate a Phase 1 clinical trial of its lead drug candidate, TTI-621 (SIRPaFc), in solid tumors and mycosis fungoides. Patient enrollment is anticipated to commence by the end of the year. Trillium is developing TTI-621 as a novel checkpoint inhibitor of the innate immune system, and the drug is currently being evaluated in an ongoing Phase 1 dose escalation study in patients with relapsed or refractory hematologic malignancies.

For the full press release, click here

Previous
Previous

Zymeworks’ ZW25 and ZW33 Granted Orphan Drug Designation for Ovarian Cancer by FDA

Next
Next

Profound Medical Appoints Arun Menawat as CEO